

**Zoono Group Limited (ASX: ZNO)
ASX ANNOUNCEMENT**

20th February 2020

Zoono & Eagle Execute Distribution Agreement for China

Zoono Group Limited (**Company**) (ASX: ZNO) is pleased to announce that it has entered into a Distribution Agreement with Eagle Health Holdings Limited (ASX: EHH) ("Eagle") for the distribution of Zoono and Eagle co-branded products and offline retail sales in China.

Zoono and Eagle have established a "co-branding" arrangement whereby Eagle will import Zoono's products in bulk to its facility in Xiamen, China, for packaging, labelling and distribution. Under the co-branding arrangement, Zoono's formulations will carry the Eagle logo and show that it is "formulated by (or powered by) Zoono".

Eagle has collectively more than 300 Zhang Lao San exclusive product stores and franchised stores throughout China, with a further 271 distribution partners placing Eagle's branded products into more than 30,000 outlets across the country.

In part due to the Coronavirus (type 'Covid-19') pandemic there is now unprecedented interest in Zoono technology and its proven activity against 'corona type' viruses and bacteria as well as its ability to prevent cross contamination with its 24 hour to 30 day extended efficacy (by application).

Eagle is receiving accelerated co-operation from the local government to expand its pharmaceutical facilities and registrations to facilitate the packaging and distribution of Zoono products. Chinese authorities are placing top priority on assisting companies with products and services associated with combating and controlling the spread of the Coronavirus. On this basis and from the most recent dialogue with the local authorities, Eagle expects the appropriate licenses to be granted to the Xiamen facility on completion of inspection in the coming days.

Key terms of the Agreement:

1. An initial 3-year term with 5-year rights of renewal;
2. Minimum purchase volumes of:
 - NZD\$1,500,000 in the first 12 months;
 - NZD\$2,300,000 in year two; and
 - NZD\$3,100,000 in year three;and thereafter increasing by 10% per annum.
3. The Initial Order of Zoono product is NZD\$400,000;
4. For sale in offline retail and Eagle co-branded products in China;
5. Eagle may sell Zoono branded (sole label) products as a preferred partner subject to good faith negotiations after 12 months in additional channels.

This announcement has been authorised and approved for release to ASX by the Board of Zoono Group Limited.

For further information, please contact:

Zoono Group Limited

Paul Hyslop

Managing Director/CEO

M: +64 21 659 977

E: paul.hyslop@zoono.com.

About Zoono

Zoono Group Limited is a global biotech company that develops, manufactures and distributes a suite of scientifically-validated, long-lasting and environmentally-friendly antimicrobial solutions. Zoono's mission is to improve health and well-being through innovative, safe, non-toxic and durable germ protection.

Zoono produces sprays, wipes and foams suited for skin care, surface sanitisers, and mould remediation treatments. The products are based on the 'zoono molecule', a unique antimicrobial molecule that bonds to any surface and kills pathogens including bacteria, viruses, algae, fungi and mould.

Zoono's products have received numerous regulatory approvals and the company's technology claims are supported by independent testing conducted in laboratories worldwide. Zoono is headquartered in New Zealand and its products are available globally.

To learn more, please visit: www.zoono.com

About Eagle Health Holdings Limited

Eagle is an ASX listed vertically integrated health and nutritional products business which develops, manufactures and distributes products into 26 provinces in China. Eagle has collectively more than 300 Zhang Lao San exclusive product stores and franchised stores throughout China, with a further 271 distribution partners placing Eagle's branded products into more than 30,000 outlets across the country. Eagle produces a range of traditional Chinese Medicine and Western nutritional products including amino acids, protein supplements, lozenges and dendrobium oil.

Eagle has a GMP certified manufacturing facility and a Head Office in Xiamen, China, acting as a central hub for distribution into Chinese pharmacies, health food stores, trading companies and supermarkets. Eagle has a corporate and sales office in Melbourne, Australia. Eagle has a stated strategy of acquiring or partnering with quality Australian products for distribution into China.